1[1]Takenouchi T,Sakagawa E,Sugawara M.Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones[J]. Antimicrob Agents Chemother, 1999, 43(2): 406-409.
2[2]Mouneimne H, Jarlier V, Cambau E, et al. Type Ⅱ topoisomerase mutations in ciprofloxacin-resistance strains of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999, 43(1): 62-66.
3[3]Li XZ, Livermore DM, Nikaiclo H. Role of efflux pumps in intrinsic resistance of Pseudomonas aeruginosa resistance to tetracycline, chloramphenicol and norfloxacin[J]. Antimicrob Agents Chemother, 1994, 38: 1732-1741.
4[4]Poole K, Bianco N, Neshat S, et al. Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1997, 41: 853-856.
5[5]Masuda N, Gotoh N, Ohya S, et al. Quantitative correlation between susceptibility and oprJ production in nfxB mutations of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1996, 40: 903-909.
6[4]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing[S]. Twelfth informantional supplement. 2002. 21(1): M100-s12.
7[5]Udo EE, Al Sweih N, John P, et al. Antibiotic resistance of enterococci isolated at a teaching hospital in Kuwait[J]. Diagn Microbiol Infect Dis, 2002, 43(3): 233-238.
8[7]Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes[J]. J Antimicrob Chemother, 2001, 48, Suppl 1: 87-102.
